Knight Operating Income from 2010 to 2026
| GUD Stock | CAD 5.76 0.07 1.20% |
Operating Income | First Reported 2012-09-30 | Previous Quarter -3.7 M | Current Value 646 K | Quarterly Volatility 3.9 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 64.1 M, Interest Expense of 9.2 M or Selling General Administrative of 26.3 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.31 or PTB Ratio of 1.11. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Operating Income |
Latest Knight Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Knight Therapeutics over the last few years. Operating Income is the amount of profit realized from Knight Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Knight Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Knight Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Knight Operating Income Regression Statistics
| Arithmetic Mean | (2,013,098) | |
| Coefficient Of Variation | (354.85) | |
| Mean Deviation | 5,514,567 | |
| Median | (5,031,819) | |
| Standard Deviation | 7,143,454 | |
| Sample Variance | 51T | |
| Range | 25.3M | |
| R-Value | 0.61 | |
| Mean Square Error | 34.2T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | 862,557 | |
| Total Sum of Squares | 816.5T |
Knight Operating Income History
About Knight Therapeutics Financial Statements
Knight Therapeutics investors utilize fundamental indicators, such as Operating Income, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 8.5 M | 8.9 M |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.